SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : TGEN - Targeted Genetics Corporation -- Ignore unavailable to you. Want to Upgrade?

To: tktrimbath who wrote (454)2/7/2006 11:56:47 PM
From: 9wald9Respond to of 557
 
HIV vaccine trial sponsored by IAVI
Monday, February 06, 2006 at 12:06EST

"The Uganda Virus Research Institute (UVRI), in collaboration
with the International AIDS Vaccine Initiative (IAVI) and
Targeted Genetics, Launches HIV/AIDS Vaccine Trial in Entebbe,
Uganda"

Targeted Genetics Corporation (Nasdaq:TGEN), The Uganda Virus
Research Institute (UVRI), and the International AIDS Vaccine
Initiative (IAVI), today announced the start of a Phase II
clinical trial in Uganda to evaluate the safety and
immunogenicity of tgAAC09, a preventive HIV/AIDS vaccine. This
is the second IAVI-sponsored HIV vaccine trial to be conducted
in Uganda. ...
Source: Business Wire



To: tktrimbath who wrote (454)3/7/2006 1:09:02 PM
From: Mike McFarlandRead Replies (1) | Respond to of 557
 
tgen is up a dime over the past couple days,
or about 15%. I don't see any news, but
the volume is three times average today so far.

On balance I think that Tgen is essentially
broke--but they will report 2005 results on
Thursday before the open.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News